You have successfully logged out.
Backing up cardiologists with unparalleled clinical data and proven performance for both paclitaxel and sirolimus coated balloons.
Cooperation: Cardiovascular News
Dr. Tuomas Rissanen (North Karelia Central Hospital, Joensuu, Finland) speaks to Cardiovascular News about the benefits of using a drug coated balloon, the clinical indications that are most suited and why a wide set of data is key.Read the article
Paclitaxel and sirolimus coated balloons
Paclitaxel coated balloon
B. Braun´s paclitaxel coated balloon SeQuent® Please NEO is the best investigated DCB  in the field of percutaneous coronary interventions (PCI). It has demonstrated its convincing performance, efficacy and safety in more than 110 published studies (including more than 35 RCTs) – with over 25,000 documented patients, conducted in more than 20 countries.
2020 | Primary Investigator: Jeger R | Study Aim: SQP vs. DES, Vessel: RD ≤ 3 mm | (Primary) Endpoint: MACE @ 36-month follow-up | Patients: 758Summary BASKET-SMALL 2
2017 | Primary Investigator: Funatsu A | Study Aim: DCB vs. POBA, Vessel: RD ≤ 2.75 mm, ≥ 2 mm | (Primary) Endpoint: TVF @ 6-month follow-up | Patients: 135Summary PEPCAD Japan SVD
2017 | Primary Investigator: Gobić D | Study Aim: DCB vs. DES, Patients: STEMI (< 12 h) | (Primary) Endpoint: MACE, LLL @ 6-month follow-up | Patients: 75Summary AMI Feasibility Study
2016 | Primary Investigator: Nishiyama N | Study Aim: DCB vs. DES | (Primary) Endpoint: TLR @ 8-month follow-up | Patients: 60Summary Clinical Value "Stent-less" PCI
2019 | Primary Investigator: Rosenberg M | Study Aim: DCB – ISR & De Novo | (Primary) Endpoint: TLR @ 9-month follow-up | Patients: 1,025Summary DCB-only All-Comers Registry
2016 | Primary Investigator: Shin E | Study Aim: DCB – De Novo, Vessel: RD ≤ 3.5 mm, ≥ 2.5 mm | (Primary) Endpoint: LLL, FFR @ 9-month follow-up, MI, TLR @ 12-month follow-up | Patients: 67Summary FFR-Guided DCB-Angioplasty
2014 | Primary Investigator: Zeymer U | Study Aim: DCB – De Novo, Vessel: RD ≤ 2.75 mm, ≥ 2.0 mm | (Primary) Endpoint: TLR @ 9-month follow-up | Patients: 447Summary SVD Registry
2023 | Primary Investigator: Shin ES | Study Aim: Investigate the impact of DCB-based treatment on PCI for multivessel CAD | (Primary) Endpoint: MACE @ 24-months (cardiac death, MI, TVR, stroke, stent thrombosis and major bleeding) | Patients: 508Summary DCB-based PCI in Multi-Vessel-Disease
Sirolimus coated balloon
B. Braun´s new sirolimus coated balloon is the first SCB backed up with published randomized clinical trials for ISR and de-novo lesions. , ,  SeQuent® SCB now offers new implant-free options for treating coronary ISR and de-novo lesions, providing excellent results in targeted drug delivery and sirolimus persistence. The combination of sirolimus and BHT (Butylated Hydroxy Toluol) creates the desired crystalline sirolimus modification to reach best results regarding sirolimus vessel wall content compared to other excipients. 
Two RCTs for SeQuent® SCB vs. SeQuent® Please NEO with angiographic and clinical follow-ups.Read summary
RCT for SeQuent® SCB vs. SeQuent® Please NEO with angiographic and clinical follow-ups.Read summary
Acceptable angiographic result
Unacceptable angiographic result
DCB-only with with SeQuent® Please NEO or SeQuent® SCB
SeQuent® Please NEO
Clinically proven drug coated balloon catheter
pdf, 1.2 MB
Sirolimus coated balloon catheter for PTCA
pdf, 1.7 MB
SeQuent® Please NEO – Go Implant-Free!
Safe and effective alternative to DES in de novo lesions
pdf, 27.8 KB
Your partner for coronary angioplasty
pdf, 1.8 MB
 All numbers referring to clinical coronary trials on PCBs, patients enrolled therein and countries in which these trials were conducted, are based on a PubMed literature search conducted with due diligence in February/March 2022. (Data on file at B. Braun)
 Ali RM et al J Am Coll Cardiol Intv 2019;12:558-66
 Scheller B et al. Circ Cardiovasc Interv. 2022 Sep;15(9):e012305.
 Ahmad WAW et al. JACC Cardiovasc Interv. 2022 Apr 11;15(7):770-779
 Clever et al. Circ Cardiovasc Interv. 2016 Apr;9(4):e003543.
 Kleber FX et al. Clin Res Cardiol. 2013 Nov;102(11):785-97.
 Jeger RV et JACC Cardiovasc Interv. 2020 Jun 22;13(12):1391-1402.